SV2006002311A - NEW COMPOUNDS REF. PC32649A - Google Patents

NEW COMPOUNDS REF. PC32649A

Info

Publication number
SV2006002311A
SV2006002311A SV2005002311A SV2005002311A SV2006002311A SV 2006002311 A SV2006002311 A SV 2006002311A SV 2005002311 A SV2005002311 A SV 2005002311A SV 2005002311 A SV2005002311 A SV 2005002311A SV 2006002311 A SV2006002311 A SV 2006002311A
Authority
SV
El Salvador
Prior art keywords
rent
alcoxi
members
heteroatomo
heterocicle
Prior art date
Application number
SV2005002311A
Other languages
Spanish (es)
Inventor
Paul Vincent Fish
Thomas Ryckmans
Alan Stobie
Florian Wakenhut
Gavin Alistair Whitlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SV2006002311A publication Critical patent/SV2006002311A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Abstract

UN COMPUESTO DE FORMULA (I): VER FORMULA;Y SUS DERIVADOS FARMACEUTICA Y/O VETERINARIAMENTE ACEPTABLE, EN LA QUE R1, R2, R3 Y R20 SON CADA UNO INDEPENDIENTEMENTE H, CL, BR, F, I, CF3, OCF3, ME, O EL;R4 ES HET O CICLOALQUILO DE C3-7 CADA UNO INDEPENDIENTEMENTE CON ALQUILO C1-4 ALCOXI DE C1-4, ALCOXIALQUILO QUE CONTIENE DE 2 A 4 ATOMOS DE CARBONO, O S-(ALQUILO DE C1-4); A ES 0 Ò 1; YHET ES UN HETEROCICLO NO AROMATICO DE 4, 5, Ò 6 MIEMBROS,, QUE CONTIENE POR LO MENOS UN HETEROATOMO DE N, O Ò S, OPCIONALMENTE CONDENSADO CONM UN GRUPO CARBOCICLICO DE 5 Ò 6 MIEMBROS O UN SEGUNDO HETEROCICLO DE 4, 5, Ò 6 MIEMBRS QU CNTIENE POR LO MENOS UN HETEROATOMO DE N, O Ò S, EN EL QUE EL GRUPOE HET ESTA OPCIONALMENTE SUSTITUIDO POR O MENOS CON UN SUBSTITUYENTE SELECCIONADO INDEPENDIENTEMENTE DE ALQUILO DE C1-8. ALCOXI DE C1-8, OH, HALO, CF3. OCF3, SCF3, HIDROXI-ALQUILO DE C1-6, ALCOXI DE C1-4,- ALQUILO DE C1-6 Y ALQUILO DE C1-4-S-ALQUILO DE C1-4; CON TAL DE QUE POR LO MENOS UNO DE R1, R2, Y R3 SEA DISTITNTO DE H, LOS COMPUESTOS DE LA INVENCION EXHIBEN ACTIVIDAD COMO INHIBIDORES DE LA RECAPTACION TANTO DE SEROTONINA COMO NORADRENONALINA Y POR LO TANTO TIENEN UTILIDD EN VARIAS AREAS TERAPEUTICAS, POR EJEMEPLO, INCONTINENCIA URINARIAA FORMULA COMPOUND (I): SEE FORMULA; AND ITS PHARMACEUTICAL AND / OR VETERINARILY ACCEPTABLE DERIVATIVES, IN WHICH R1, R2, R3 AND R20 ARE EACH INDEPENDENTLY H, CL, BR, F, I, CF3, OCF3, ME , OR EL; R4 IS HET OR C3-7 CYCLALKYL EACH ONE WITH INDEPENDENTLY WITH C1-4 ALCOXI C1-4, ALCOXIALQUIL CONTAINING OF 2 TO 4 CARBON ATOMS, OR S- (C1-4 RENT); A ES 0 Ò 1; YHET IS A NON-AROMATIC HETEROCICLE OF 4, 5, Ò 6 MEMBERS ,, THAT CONTAINS AT LEAST ONE HETEROATOMO OF N, OR Ò S, OPTIONALLY CONDENSED WITH ME A CARBOCICLIC GROUP OF 5 Ò 6 MEMBERS OR A SECOND HETEROCICLE OF 4, 5, 5, 5 Ò 6 MEMBERS WHO HAVE AT LEAST ONE HETEROATOMO OF N, OR Ò S, IN WHICH THE GROUP HET IS OPTIONALLY REPLACED BY OR UNLESS WITH A SUBSTITUENTLY SELECTED FROM A RENT OF C1-8. ALCOXI OF C1-8, OH, HALO, CF3. OCF3, SCF3, HYDROXI-RENT OF C1-6, ALCOXI OF C1-4, - RENT OF C1-6 AND RENT OF C1-4-S-RENT OF C1-4; SUCH AS AT LEAST ONE OF R1, R2, AND R3 IS DISTRICT OF H, THE COMPOUNDS OF THE INVENTION EXHIBIT ACTIVITY AS INHIBITORS OF THE RECAPTATION OF BOTH SEROTONINE AS NORADRENONALINE AND THEREFORE THEY HAVE BEEN USED IN VARIOUS THERAPY THERAPY ETHICAL AREAS , URINARY INCONTINENCE

SV2005002311A 2004-11-23 2005-11-23 NEW COMPOUNDS REF. PC32649A SV2006002311A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0425766.3A GB0425766D0 (en) 2004-11-23 2004-11-23 Novel compounds

Publications (1)

Publication Number Publication Date
SV2006002311A true SV2006002311A (en) 2006-09-14

Family

ID=33548739

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002311A SV2006002311A (en) 2004-11-23 2005-11-23 NEW COMPOUNDS REF. PC32649A

Country Status (26)

Country Link
EP (1) EP1817281A1 (en)
JP (1) JP4233596B2 (en)
KR (1) KR100886294B1 (en)
CN (1) CN101065355A (en)
AP (1) AP2007004003A0 (en)
AR (1) AR052243A1 (en)
AU (1) AU2005308534A1 (en)
BR (1) BRPI0518486A2 (en)
CA (1) CA2589258A1 (en)
CR (1) CR9171A (en)
EA (1) EA011217B1 (en)
GB (1) GB0425766D0 (en)
GT (1) GT200500337A (en)
IL (1) IL183191A0 (en)
MA (1) MA29038B1 (en)
MX (1) MX2007006138A (en)
NL (2) NL1030485C2 (en)
NO (1) NO20072486L (en)
PA (1) PA8653501A1 (en)
PE (1) PE20061056A1 (en)
SV (1) SV2006002311A (en)
TN (1) TNSN07201A1 (en)
TW (1) TWI300776B (en)
UY (1) UY29224A1 (en)
WO (1) WO2006056884A1 (en)
ZA (1) ZA200703910B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
JP4137159B2 (en) * 2003-06-17 2008-08-20 ファイザー・インク N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline reuptake inhibitors

Also Published As

Publication number Publication date
GT200500337A (en) 2006-06-13
KR100886294B1 (en) 2009-03-04
UY29224A1 (en) 2006-06-30
GB0425766D0 (en) 2004-12-22
CR9171A (en) 2007-07-04
KR20070086599A (en) 2007-08-27
EA011217B1 (en) 2009-02-27
NL1030485C2 (en) 2006-11-07
MX2007006138A (en) 2007-07-19
ZA200703910B (en) 2008-09-25
WO2006056884A1 (en) 2006-06-01
EP1817281A1 (en) 2007-08-15
IL183191A0 (en) 2007-08-19
AU2005308534A1 (en) 2006-06-01
AR052243A1 (en) 2007-03-07
JP4233596B2 (en) 2009-03-04
MA29038B1 (en) 2007-11-01
TWI300776B (en) 2008-09-11
AP2007004003A0 (en) 2007-06-30
TW200626543A (en) 2006-08-01
NO20072486L (en) 2007-06-20
TNSN07201A1 (en) 2008-11-21
BRPI0518486A2 (en) 2008-11-18
CN101065355A (en) 2007-10-31
NL1030485A1 (en) 2006-05-24
PA8653501A1 (en) 2006-06-02
CA2589258A1 (en) 2006-06-01
NL1032760A1 (en) 2006-12-13
NL1032760C2 (en) 2007-04-17
PE20061056A1 (en) 2006-11-08
EA200700920A1 (en) 2007-12-28
JP2008520646A (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ECSP056232A (en) NEW COMPOUNDS
ECSP13012771A (en) SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUNDS FUSED IN POSITION 6.6 AND USES OF THE SAME
AR056327A1 (en) NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
MX2013004242A (en) Nematocidal sulfonamides.
EA201000484A1 (en) THYENOPYRIMIDINE AND PYRAZOLOPIRIMIDIN COMPOUNDS AND THEIR APPLICATION AS INHIBITORS MTOR KINASE AND PI3 KINASE
AR078157A1 (en) DERIVATIVES OF PIRAZOL- [4,5-D] PIRROLO [2,3-B] PYRIDINE INHIBITORS OF JAK 2 THYROSINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF CANCER
EA200701176A1 (en) NEW NAPHTHALINE COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR059925A1 (en) FORMULATIONS
AR074358A1 (en) PIRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10
MX2011011485A (en) Nematocidal sulfonamides.
TNSN07471A1 (en) Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
CL2004000917A1 (en) COMPOUNDS DERIVED FROM TIAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF DISEASES MEDIATED BY DOSFATIDILNOSITOL 3-KINASE SUCH AS RESPIRATORY DISEASES, ALLERGIES, Rheumatoid Arthritis, OSTEOA
BRPI0711310B8 (en) p38 map kinase inhibitor compound, pharmaceutical composition comprising the same and use thereof
ECSP099335A (en) HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND METHODS OF USE OF THE SAME
AR082536A1 (en) DERIVATIVES OF 5-IODO-TRIAZOL
ECSP099216A (en) NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY29070A1 (en) FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES
UY29749A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USE AS MEDICATIONS
CO6150157A2 (en) DERIVATIVES OF 7-ALQUINIL-1,8- NAFTIRIDONAS ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
NO20091817L (en) Kinase inhibitors
AR073043A1 (en) COMPOUNDS OF POLYSUSTITUTED AZETIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY, METABOLIC DISEASES AND OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHERS.
CR9499A (en) NEW DERIVATIVES OF PHENYLPIRIDINYLPIPERAZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO6321159A2 (en) USED FUSIONED PIRAZINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
CO6180429A2 (en) PHARMACEUTICAL AGENT CONTAINING A HER2 INHIBITOR AND A HORMONAL THERAPEUTIC AGENT OR ANTI-BANERIGEN AGENT IN COMBINATION
AR054418A1 (en) QUINAZOLINAS PIRAZOLAMINO SUBSTITUTED. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.